ESMO 2023: Highlights and analysis
8 Nov 2023
ESMO 2023: Highlights and analysis
Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
CAR-T therapy and impact to cancer patient outcomes and experience of treatment
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer
Hope vs Hype of evidence interpretation
Haemato-oncological Cancers
Gynaecological Cancers
Challenges in evidence interpretation overcoming biases
Lung Cancer
Head and Neck Cancers
Real world evidence research asking the right question